Abstract Number: 2581 • 2015 ACR/ARHP Annual Meeting
TNF-Alpha Receptor II Signaling Plays an Important Role in Maintaining the Expression of Forkhead Box P3 in Murine Regulatory T Cells
Background/Purpose: TNF-α is a key regulator of inflammation, which induces signal transduction by binding to two structurally and functionally distinct receptors on target cells: TNF…Abstract Number: 2594 • 2015 ACR/ARHP Annual Meeting
Multi-Biomarker Disease Activity Score As a Predictor of Flare in Patients with Rheumatoid Arthritis Who Stop TNF-Alpha-Inhibitor Therapy
Background/Purpose: Prediction which rheumatoid arthritis (RA) patients in low disease activity (LDA) can successfully discontinue TNF inhibition (TNFi) may improve the cost-effectiveness of RA management.…Abstract Number: 3170 • 2015 ACR/ARHP Annual Meeting
Peripheral Osteoblastogenesis in Rheumatoid Arthritis Is Enhanced after TNF Blocker Treatment, Irrespective of Systemic Inflammation
Background/Purpose: We investigated osteoclastogenesis and osteoblastogenesis in peripheral blood before and 6 months after TNF blocker treatment in seropositive RA patients. Methods: Seventeen seropositive…Abstract Number: 910 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor-Alpha Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Background/Purpose: Results from several small studies support the potential blood pressure lowering effect of tumor necrosis factor (TNF)-a inhibitors in rheumatoid arthritis (RA) patients. Yet,…Abstract Number: 1096 • 2015 ACR/ARHP Annual Meeting
B Cells Are Prime Producers of Tumor Necrosis Factor Alpha in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease, which causes joint inflammation and bone loss. Inflammation-mediated joint damage is linked to the imbalance of…Abstract Number: 1364 • 2015 ACR/ARHP Annual Meeting
Treating Experimental Arthritis with the Innate Immune Inhibitor IL-37 Reduces Joint and Systemic Inflammation
Background/Purpose: Characterized as a fundamental inhibitor of innate inflammation, IL‑1 family member IL‑37 is expressed in the synovia of patients with rheumatoid arthritis. We investigated…Abstract Number: 2464 • 2014 ACR/ARHP Annual Meeting
Anti-Arthritic Effect of Tubastatin A, a Novel Histone Deacetylases-6 Inhibitor, Is Mediated By Stabilization of IkB Via Suppression of Ubiquitin-Proteasome Pathway
Background/Purpose: Histone deacetylase-6 (HDAC-6) functions as a non-epigenetic deacetylase for non-histone substrates and regulates microtubule-mediates processes such as cell migration, cell cycle arrest, and angiogenesis.…Abstract Number: 2369 • 2014 ACR/ARHP Annual Meeting
Management of Perioperative Tumor Necrosis -á Inhibitors in Rheumatoid Arthritis Undergoing Arthroplasty: A Systematic Review and Meta-Analysis
Background/Purpose: Tumor Necrosis Factor α inhibitors (TNFi) are widely used in patients with RA (Rheumatoid Arthritis) undergoing orthopedic surgery, yet its optimal perioperative management is…Abstract Number: 2370 • 2014 ACR/ARHP Annual Meeting
Management of Perioperative Tumor Necrosis Factor α Inhibitors in Rheumatoid Arthritis Undergoing Arthroplasty: A Systematic Review and Meta-Analysis
Background/Purpose: Tumor Necrosis Factor α inhibitors (TNFi) are widely used in patients with RA (Rheumatoid Arthritis) undergoing orthopedic surgery, yet its optimal perioperative management is…Abstract Number: 1909 • 2014 ACR/ARHP Annual Meeting
Incidence of Congestive Heart Failure in Subjects with Rheumatoid Arthritis Receiving Anti-Tumour Necrosis Factor Drugs: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Background/Purpose Subjects with rheumatoid arthritis (RA) are at a higher risk of developing cardiovascular (CV) disease compared to the general population, with an increased incidence…Abstract Number: 846 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis, Anti-Tumor Necrosis Factor Therapy, and Risk of Squamous Cell and Basal Cell Skin Cancer- a Nationwide Population Based Prospective Cohort Study from Sweden
Background/Purpose: There is a concern that tumor necrosis factor inhibitors (TNFi) may interplay with tumor biology and increase the risk of cancer, in particular cancer…Abstract Number: 484 • 2014 ACR/ARHP Annual Meeting
Reactivation of Hepatitis B Virus in Patients with Rheumatoid Arthritis after Anti-TNF Therapy
Background/Purpose: Anti-TNF therapy was known to increase the risk of certain infection. There are only limited data about the reactivation of hepatitis B virus (HBV)…Abstract Number: 1427 • 2013 ACR/ARHP Annual Meeting
Discovery and Characterization Of ABT-122, An Anti-TNF/IL-17 DVD-Ig™ Molecule As a Potential Therapeutic Candidate For Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a serious autoimmune disease that significantly impacts patients’ quality of life. Several approved biologic drugs targeting tumor necrosis factor (TNF)…Abstract Number: 1434 • 2013 ACR/ARHP Annual Meeting
Assessing Janus Kinase inhibitor’s Place In Therapy In Established Rheumatoid Arthritis Patients – From a Simplified Indirect Comparison Versus Tumor Necrosis Factor Inhibitors To a Bayesian Probability Of Response – The Value Of Transparency
Background/Purpose: Bayesian style network meta-analyses and mixed treatment comparisons help address potential bias from effect modifying trial covariates within indirect comparisons and are theoretically easier…Abstract Number: 1435 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of TNF-á Inhibitor Therapy Does Not Differ Between Elderly and Younger Patients With Rheumatoid Arthritis: Results From The Corrona Registry
Background/Purpose: Biologics have revolutionized the therapy and prognosis of patients (pts) with Rheumatoid Arthritis (RA). Studies evaluating whether the effectiveness of TNF-α inhibitor (TNFi) therapy…
ACR Meeting Abstracts